Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of the 2010–2011 Northern Hemisphere Inactivated Split-Virion Influenza Vaccine (Intramuscular)
2009-017690-38Phase 3Completed
- Sponsor
- Sanofi
- Start
- Mar 2010
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, single-arm trial of inactivated influenza vaccine (split virion) in influenza, sponsored by Sanofi. Primary endpoints: Primary immunogenicity and Safety. Started Mar 2010; status: completed.
02
Drugs
inactivated influenza vaccine (split virion)
03
Conditions
influenza
Beyond the preview
Go deeper on 2009-017690-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017690-38.